Neurocrine Bio. (NBIX) PT Raised to $135 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
August 1, 2018 7:16 AM EDTNeedham & Company raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $125.00 (from $110.00) while maintaining a Buy rating.
Analyst Alan Carr commented, "Neurocrine reported $96.9M in 2Q18 Ingrezza sales, above our $85.0M and consensus $84M ests. Mgmt still not providing sales guidance, but... More
Neurocrine Bio. (NBIX) PT Raised to $131 at Baird
August 1, 2018 6:58 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $122.00) while maintaining an Outperform rating on continued strength in Ingrezza launch.
Analyst Brian Skorney commented, "Neurocrine reported earnings, with net sales of Ingrezza coming in well ahead of expectations at $96.9M.... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
July 31, 2018 4:04 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.07), $0.10 better than the analyst estimate of ($0.17).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More